DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Lung Heart Rate Variability

Not Applicable

Withdrawn

Conditions: Non Small Cell Lung Cancer

Interventions: Behavioral: Heart Rate Variability Biofeedback Training

First Posted Date: 2018-09-17

Last Posted Date: 2020-04-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT03674450

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Phase 2

Recruiting

Conditions: Metastatic Melanoma

Interventions: Drug: Nivolumab
Radiation: Hypofractionated Radiation Therapy (HFRT)
Drug: Ipilimumab

First Posted Date: 2018-08-24

Last Posted Date: 2025-02-12

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 54

Registration Number: NCT03646617

Locations: 🇺🇸
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
🇺🇸
Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Lancaster General Hospital, Lancaster, Pennsylvania, United States

A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer

Completed

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2018-08-06

Last Posted Date: 2020-02-20

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 25

Registration Number: NCT03616522

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas

Phase 1

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2018-07-13

Last Posted Date: 2021-05-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT03586024

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment

Phase 1

Terminated

Conditions: Recurrent Glioblastoma

Interventions: Biological: [18F]fluoromisonidazole
Drug: Bevacizumab
Radiation: positron emission tomography (PET/CT).

First Posted Date: 2018-06-29

Last Posted Date: 2020-02-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 2

Registration Number: NCT03573986

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Early Stage Non-Small Cell Lung Cancer

Interventions: Drug: Vancomycin
Radiation: Precision hypofractionated radiation

First Posted Date: 2018-06-06

Last Posted Date: 2024-07-30

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT03546829

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

Completed

Conditions: Prostate Cancer

Interventions: Device: myocardial PET imaging

First Posted Date: 2018-05-24

Last Posted Date: 2024-11-19

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 18

Registration Number: NCT03535987

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Early Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Nivolumab
Drug: Nab-Paclitaxel
Drug: Gemcitabine
Drug: Paricalcitol

First Posted Date: 2018-05-08

Last Posted Date: 2024-03-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 3

Registration Number: NCT03519308

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Genetics and Heart Health After Cancer Therapy

Completed

Conditions: Breast Cancer
Hereditary Breast/Ovarian Cancer (brca1, Brca2)
Heart Diseases
Drug-Induced Cardiomyopathy

Interventions: Diagnostic Test: echocardiography
Other: Cardiopulmonary Exercise Testing
Other: Blood Collection

First Posted Date: 2018-04-27

Last Posted Date: 2024-10-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 79

Registration Number: NCT03510689

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

Phase 2

Terminated

Conditions: Hodgkin Lymphoma

Interventions: Drug: Nivolumab

First Posted Date: 2018-04-12

Last Posted Date: 2024-01-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 7

Registration Number: NCT03495713

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy